References
1. Australian Institute of Health and Welfare. Deaths involving alcohol and other drugs. Canberra: AIHW. 2026 Jul 1. At: Alcohol, tobacco & other drugs in Australia: Deaths involving alcohol and other drugs – Australian Institute of Health and Welfare
2. Jauncey M, Nielsen S. Naloxone for opioid toxicity and overdose in the community. Aust Prescr 2021;44(2):38–9.
3. Australian and New Zealand Committee on Resuscitation (ANZCOR). Guideline 9.5.2: first aid management of opioid overdose. Melbourne: ANZCOR. 2024. At: Guideline 9.5.2 – First Aid Management of Suspected Opioid Overdose
4. Australian Government Department of Health and Aged Care. Take-Home Naloxone Program. Canberra: Commonwealth of Australia. 2026. At: Take Home Naloxone program | Australian Government Department of Health, Disability and Ageing
5. Department of Health (Victoria). Victoria’s Take-Home Naloxone program. Melbourne: Victorian Government. 2026. At: www.health.vic.gov.au/aod-treatment-services/victorias-take-home-naloxone-program
6. Hill PL, et al. Mortality in the SuperMIX cohort of people who inject drugs in Melbourne, Australia: a prospective observational study. Addiction 2022;117(12):3091–8.
7. Nielsen S, et al. Knowledge of opioid overdose and attitudes to supply of Take-Home Naloxone among people with chronic noncancer pain prescribed opioids. Pain Med 2018;19(3):533–40.
8. Cann G. Neighbour smashed his way into Broadmeadows house with mallet before discovering overdose victims, court hears. ABC News. 2025 Apr 15. At: Neighbour smashed his way into Broadmeadows house with mallet before discovering overdose victims, court hears – ABC News
9. Mammoliti E, Nielson S, Roxburgh A. A scoping review of the emergence of novel synthetic opioids in Australian drug markets: what does this mean for harm reduction responses? Drug Alcohol Rev 2025;45(1):e14079.
10. Nielsen S, et al. Behavioural effects and naloxone effectiveness with new synthetic opioids. Drug Alcohol Rev 2026;45(1):e70040.
11. Davis MP, DiScala S, Davis A. Respiratory depression associated with opioids: a narrative review. Curr Treat Options Oncol 2024;25(11):1438–50.
12. Buckley N, ed. Australian medicines handbook. 2026.
13. Hong JS, et al. Neurologic, cognitive, and behavioral consequences of opioid overdose: a review. Curr Phys Med Rehabil Rep 2019;7(4):305–13.
14. Stolbach A. Acute opioid intoxication in adults. UpToDate. Waltham (MA): UpToDate Inc. 2026. At: www.uptodate.com/contents/acute-opioid-intoxication-in-adults
15. Opioid Safety Toolkit. Opioid safety toolkit. At: www.saferopioiduse.com.au
16. Therapeutic Guidelines. Opioids in pain management [amended Jul 2024]. In: eTG complete. Melbourne: Therapeutic Guidelines Limited. 2026.
17. Strang J, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs 2019;79(13):1395–418.
18. Seltzer J, et al. Naloxone infusions for opioid overdose: a 10-year retrospective analysis. J Emerg Med 2026;86:45–51.
19. The Royal Women’s Hospital. Naloxone: pregnancy and breastfeeding medicines guide (PBMG). Melbourne: The Royal Women’s Hospital. 2026. At: www.thewomenspbmg.org.au/medicines/naloxone
20. Blandthorn J, Bowman E, Leung L, et al. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gynaecol 2018;58(4):460–2.
21. Picco L, et al. Provision of harm reduction services in community pharmacies: findings from an Australian national sample. Int J Drug Policy 2026;154:105351.
22. NSW Health. Naloxone: NSW take home naloxone program. Sydney: NSW Health. 2026. At: www.health.nsw.gov.au/aod/programs/Pages/naloxone.aspx
23. Farrugia A, Neale J, Dwyer R, et al. Conflict and communication: managing the multiple affordances of take-home naloxone administration events in Australia. Addict Res Theory 2020;28(1):29–37.
24. Wilson H. How stigmatising language affects people in Australia who use tobacco, alcohol and other drugs. Aust J Gen Pract 2020;49:155–8.
25. Pharmaceutical Society of Australia. Opioid safety toolkit. Canberra: Pharmaceutical Society of Australia. At: Opioid Safety Toolkit – Pharmaceutical Society of Australia.
26. NSW Users and AIDS Association (NUAA). For health professionals. Sydney: NUAA. At: www.nuaa.org.au/forhealthprofessionals
27. Wisbey M. ‘Deeply concerning’: vapes found laced with nitazene. Melbourne: Royal Australian College of General Practitioners. 2025 Aug 7. At: www1.racgp.org.au/newsgp/clinical/deeply-concerning-vapes-found-laced-with-nitazene
28. Martin J, Schumann J. Emerging risks of nitazene-adulterated vapes in Australia: balancing regulation, access and harm reduction. Drug Alcohol Rev 2026 Jan 25.
29. Sansom LN, ed. Australian pharmaceutical formulary and handbook. 26th edn. Canberra: Pharmaceutical Society of Australia. 2024. At: www.psa.org.au/media-publications/australian-pharmaceutical-formulary
30. Chronister KJ, et al. Findings and lessons learnt from implementing Australia’s first health service based take-home naloxone program. Drug Alcohol Rev 2018;37(4):464–71.
31. NSW Ministry of Health. Management of withdrawal from alcohol and other drugs: clinical guidance. Sydney: NSW Health. 2022. At: www.health.nsw.gov.au/aod/Publications/nsw-clinical-guidelines-opioid.pdf
32. Neale J, Kalk NJ, Parkin S, et al. Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: exploratory mixed methods analysis. J Subst Abuse Treat 2020;117:108099.
33. Alcohol and Drug Foundation. Opioids: drug facts. Melbourne: Alcohol and Drug Foundation. 2025. At: Opioids – Alcohol and Drug Foundation.
34. NSW Ministry of Health. Nitazenes causing severe opioid overdoses in NSW: public drug warning. Sydney: NSW Health. 2024. At: Nitazenes causing severe opioid overdoses in NSW.
